Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/- Mice

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Bisgaard, Line S ^a,b   Bosteen, Markus H ^a,c   Fink, Lisbeth N ^b   Sørensen, Charlotte M ^a   Rosendahl, Alexander ^b,d   Mogensen, Christina K ^b   Rasmussen, Salka E ^b   Rolin, Bidda ^b   Nielsen, Lars B ^a,c   Pedersen, Tanja X ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Rigshospitalet   (Denmark)

^d Medical Affairs Nordics   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE I ALPHA 1; COLLAGEN TYPE III ALPHA 1; LIRAGLUTIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GLOMERULUS; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY SIZE; LOW DENSITY LIPOPROTEIN RECEPTOR KO MOUSE; MOUSE; MOUSE MODEL; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION; UPREGULATION; UREMIA; ANIMAL; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE INACTIVATION; GENETICS; IMMUNOLOGY; KIDNEY; MALE; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROSIS; GENE KNOCKOUT TECHNIQUES; HYPOGLYCEMIC AGENTS; KIDNEY; LIRAGLUTIDE; MALE; MICE; RECEPTORS, LDL; UP-REGULATION; UREMIA;

EID: 85006414903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168396     Document Type: Article

References (43)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology: JASN. 2006; 17(7):2034-47. doi: 10.1681/ASN.2005101085 PMID: 16738019
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17):2154-69. doi: 10.1161/01.CIR.0000095676. 90936.80 PMID: 14581387
3. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
4. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012; 379(9811):165-80. doi: 10.1016/S0140-6736(11)60178-5 PMID: 21840587
5. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011). 2014; 4(1):2-8.
6. Tampe D, Zeisberg M. Potential approaches to reverse or repair renal fibrosis. Nature reviews Nephrology. 2014; 10(4):226-37. doi: 10.1038/nrneph.2014.14 PMID: 24514753
7. Bro S, Moeller F, Andersen CB, Olgaard C, Nielsen LB. Increased Expression of Adhesion Molecules in Uremic Atherosclerosis in Apolipoprotein-E-Deficient Mice. Journal of the American Society of Nephrology: JASN. 2004; 15(6):1495-503. PMID: 15153560
8. Pedersen TX, Madsen M, Junker N, Christoffersen C, Vikesa J, Bro S, et al. Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. Cardiovasc Res. 2013; 98(3):352-9. doi: 10.1093/cvr/ cvt049 PMID: 23455547
9. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. Journal of the American Society of Nephrology: JASN. 2005; 16(1):109-16. doi: 10.1681/ASN.2004060495 PMID: 15563564
10. Mori Y, Hirano T. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol. Metabolism. 2012; 61(3):379-88. doi: 10.1016/j.metabol. 2011.07.004 PMID: 21868047
11. Canaud G, Bienaime F, Viau A, Treins C, Baron W, Nguyen C, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nature medicine. 2013; 19(10):1288-96. doi: 10.1038/nm.3313 PMID: 24056770
12. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arteriosclerosis, thrombosis, and vascular biology. 2007; 27(9):1910-7. doi: 10.1161/ATVBAHA.107.147645 PMID: 17626903
13. Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. Journal of the American Society of Nephrology: JASN. 2009; 20(1):123-30. doi: 10.1681/ASN.2007111233 PMID: 19092126
14. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab. 2012; 97(1):198-207. doi: 10.1210/jc.2011-1508 PMID: 22013105
15. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diabetes & vascular disease research. 2013; 10(4):353-60.
16. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011; 54(10):2649-59. doi: 10.1007/s00125-011-2241-2 PMID: 21786155
17. Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol. 2014; 171(3):723-34. doi: 10.1111/bph.12490 PMID: 24490861
18. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012; 61(10):1422-34. doi: 10.1016/j. metabol.2012.03.002 PMID: 22554832
19. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011; 54(4):965-78. doi: 10.1007/s00125-010-2028-x PMID: 21253697
20. El-Nahas AM. Plasticity of kidney cells: role in kidney remodeling and scarring. Kidney international. 2003; 64(5):1553-63. doi: 10.1046/j.1523-1755.2003.00255.x PMID: 14531787
21. Laouari D, Burtin M, Phelep A, Martino C, Pillebout E, Montagutelli X, et al. TGF-alpha mediates genetic susceptibility to chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2011; 22(2):327-35. doi: 10.1681/ASN.2010040356 PMID: 21183591
22. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney international. 1996; 49 (3):666-78. PMID: 8648907
23. Wicks SE, Nguyen TT, Breaux C, Kruger C, Stadler K. Diet-induced obesity and kidney disease-In search of a susceptible mouse model. Biochimie. 2015.
24. Ghosh SS, Righi S, Krieg R, Kang L, Carl D, Wang J, et al. High Fat High Cholesterol Diet (Western Diet) Aggravates Atherosclerosis, Hyperglycemia and Renal Failure in Nephrectomized LDL Receptor Knockout Mice: Role of Intestine Derived Lipopolysaccharide. PloS one. 2015; 10(11):e0141109. doi: 10.1371/journal.pone.0141109 PMID: 26580567
25. Pedersen TX, Binder CJ, Fredrikson GN, Nilsson J, Bro S, Nielsen LB. The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2010; 25(8):2486-91.
26. Pedersen TX, Bro S, Andersen MH, Etzerodt M, Jauhiainen M, Moestrup S, et al. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis. 2009; 202(2):372-81. doi: 10.1016/j.atherosclerosis.2008.04.041 PMID: 18489910
27. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59(4):1030-7. doi: 10.2337/db09-1694 PMID: 20068138
28. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diabetes & vascular disease research. 2011; 8(2):117-24.
29. Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides. 2014; 54:19-26. doi: 10.1016/j.peptides.2013.12.015 PMID: 24418070
30. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nature medicine. 2015; 21(6):628-37. doi: 10.1038/nm.3866 PMID: 25985364
31. Bro S, Borup R, Andersen CB, Moeller F, Olgaard K, Nielsen LB. Uremia-specific effects in the arterial media during development of uremic atherosclerosis in apolipoprotein E-deficient mice. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26(3):570-5. doi: 10.1161/01.ATV.0000201060.47945.cb PMID: 16373611
32. Monroy MA, Fang J, Li S, Ferrer L, Birkenbach MP, Lee IJ, et al. Chronic kidney disease alters vascular smooth muscle cell phenotype. Front Biosci (Landmark Ed). 2015; 20:784-95.
33. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol. 2010; 30 (3):234-54. doi: 10.1016/j.semnephrol.2010.03.003 PMID: 20620669
34. Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney international. 2004; 66(6):2264-78. doi: 10.1111/j.1523-1755.2004.66038.x PMID: 15569315
35. Guo S, Wietecha TA, Hudkins KL, Kida Y, Spencer MW, Pichaiwong W, et al. Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney international. 2011; 80(9):946-58. doi: 10.1038/ki.2011.249 PMID: 21814168
36. Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, Cruz PE, et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. Journal of the American Society of Nephrology: JASN. 2005; 16(12):3651-60. doi: 10.1681/ASN.2005030297 PMID: 16251240
37. Duffield JS, Tipping PG, Kipari T, Cailhier JF, Clay S, Lang R, et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol. 2005; 167(5):1207-19. doi: 10. 1016/S0002-9440(10)61209-6 PMID: 16251406
38. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney international. 2010; 78(4):351-62. doi: 10. 1038/ki.2010.177 PMID: 20555323
39. Cao Q, Lu J, Li Q, Wang C, Wang XM, Lee VW, et al. CD103+ Dendritic Cells Elicit CD8+ T Cell Responses to Accelerate Kidney Injury in Adriamycin Nephropathy. Journal of the American Society of Nephrology: JASN. 2015.
40. Wang Y, Wang Y, Feng X, Bao S, Yi S, Kairaitis L, et al. Depletion of CD4(+) T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney international. 2001; 59(3):975-84. doi: 10.1046/j.1523-1755.2001.059003975.x PMID: 11231352
41. Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney international. 2016; 89(5):1049-61. doi: 10. 1016/j.kint.2016.01.016 PMID: 27083282
42. Betz B, Conway BR. Recent advances in animal models of diabetic nephropathy. Nephron Exp Nephrol. 2014; 126(4):191-5. doi: 10.1159/000363300 PMID: 25034792
43. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(23):13330-4. doi: 10.1073/ pnas.231476798 PMID: 11687636